Neural Biomarkers for Identifying Atopic Dermatitis and Assessing Acupuncture Treatment Response Using Resting-State fMRI
(Source: Journal of Asthma and Allergy)
Source: Journal of Asthma and Allergy - April 17, 2024 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
The use of essential oils in atopic dermatitis: a review
Curr Med Res Opin. 2024 Apr 16:1-32. doi: 10.1080/03007995.2024.2340734. Online ahead of print.ABSTRACTAtopic dermatitis (AD) has become a common childhood disease that affects a large number of children worldwide and has become a chronic skin disease that cause a huge economical and psychological damage to the whole family. Despite the use of steroids, immunosuppressants and various topical preparation, the prognosis is still poor. Hence, this review aimed to explore the potential of using essential oils (EO) as an active ingredient in managing AD. The review was completed by using Pubmed, Scopus and Medline to search for...
Source: Current Medical Research and Opinion - April 16, 2024 Category: Research Authors: Hanisah Azhari Ng Shiow Fern Razifah Mohd Razali Hooi Leong Loo Source Type: research
A retrospective comparison of early- and late-onset chronic actinic dermatitis: characteristics and management
Br J Dermatol. 2024 Apr 16:ljae101. doi: 10.1093/bjd/ljae101. Online ahead of print.NO ABSTRACTPMID:38625063 | DOI:10.1093/bjd/ljae101 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - April 16, 2024 Category: Dermatology Authors: Chayada Chaiyabutr Robert Dawe Andrea Lesar Sally H Ibbotson Source Type: research
Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease
ConclusionThis case report documents ulcerative keratitis occurring in association with tralokinumab therapy for AD, which has previously been described with dupilumab but not tralokinumab. This report demonstrates the need for vigilant ocular surface monitoring for patients on tralokinumab and illustrates successful management and long-term control of adverse ocular events associated with this medication. (Source: Journal of Ophthalmic Inflammation and Infection)
Source: Journal of Ophthalmic Inflammation and Infection - April 16, 2024 Category: Opthalmology Source Type: research
Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study
ConclusionTCZ can treat active moderate-to-severe TED, showing high drug compliance and reasonable response to inflammation and extraocular motility abnormality. (Source: International Ophthalmology)
Source: International Ophthalmology - April 16, 2024 Category: Opthalmology Source Type: research
Efficacy of an aloe vera, chamomile, and thyme cosmetic cream for the prophylaxis and treatment of mild dermatitis induced by radiation therapy in breast cancer patients (the Alantel study)
CONCLUSIONS: The higher efficacy of Alantel® compared to the control cream in reducing the incidence of RD in women with breast cancer has been demonstrated.PMID:38616815 | PMC:PMC11010796 | DOI:10.1016/j.conctc.2024.101288 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: E Villegas-Becerril C Jimenez-Garcia L A Perula-de Torres M Espinosa-Calvo C M Bueno-Serrano F Romero-Ruperto F Gines-Santiago M C Moreno-Manzanaro J J Mu ñoz-Gavilan G Montes-Redondo M A Quesada-Roman M C Linares-Ramirez J M Parras-Rejano N Mu ñoz-Alca Source Type: research
Efficacy of an aloe vera, chamomile, and thyme cosmetic cream for the prophylaxis and treatment of mild dermatitis induced by radiation therapy in breast cancer patients (the Alantel study)
CONCLUSIONS: The higher efficacy of Alantel® compared to the control cream in reducing the incidence of RD in women with breast cancer has been demonstrated.PMID:38616815 | PMC:PMC11010796 | DOI:10.1016/j.conctc.2024.101288 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 15, 2024 Category: Cancer & Oncology Authors: E Villegas-Becerril C Jimenez-Garcia L A Perula-de Torres M Espinosa-Calvo C M Bueno-Serrano F Romero-Ruperto F Gines-Santiago M C Moreno-Manzanaro J J Mu ñoz-Gavilan G Montes-Redondo M A Quesada-Roman M C Linares-Ramirez J M Parras-Rejano N Mu ñoz-Alca Source Type: research
Inhibition of macrophage MAPK/NF- κB pathway and Th2 axis by mangiferin ameliorates MC903-induced atopic dermatitis
Int Immunopharmacol. 2024 Apr 14;133:112038. doi: 10.1016/j.intimp.2024.112038. Online ahead of print.ABSTRACTAvailable online Atopic dermatitis (AD) is a chronic, persistent inflammatory skin disease characterized by eczema-like lesions and itching. Although topical steroids have been reported for treating AD, they are associated with adverse effects. Thus, safer medications are needed for those who cannot tolerate these agents for long periods. Mangiferin (MAN) is a flavonoid widely found in many herbs, with significant anti-inflammatory and immunomodulatory activities. However, the potential modulatory effects and mecha...
Source: International Immunopharmacology - April 15, 2024 Category: Allergy & Immunology Authors: Cheng Lu ShiJun Deng YanJiao Liu ShengJin Yang DingMei Qin LiJuan Zhang Rui-Rui Wang Yi Zhang Source Type: research
Efficacy of an aloe vera, chamomile, and thyme cosmetic cream for the prophylaxis and treatment of mild dermatitis induced by radiation therapy in breast cancer patients (the Alantel study)
CONCLUSIONS: The higher efficacy of Alantel® compared to the control cream in reducing the incidence of RD in women with breast cancer has been demonstrated.PMID:38616815 | PMC:PMC11010796 | DOI:10.1016/j.conctc.2024.101288 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 15, 2024 Category: Cancer & Oncology Authors: E Villegas-Becerril C Jimenez-Garcia L A Perula-de Torres M Espinosa-Calvo C M Bueno-Serrano F Romero-Ruperto F Gines-Santiago M C Moreno-Manzanaro J J Mu ñoz-Gavilan G Montes-Redondo M A Quesada-Roman M C Linares-Ramirez J M Parras-Rejano N Mu ñoz-Alca Source Type: research
Efficacy of an aloe vera, chamomile, and thyme cosmetic cream for the prophylaxis and treatment of mild dermatitis induced by radiation therapy in breast cancer patients (the Alantel study)
CONCLUSIONS: The higher efficacy of Alantel® compared to the control cream in reducing the incidence of RD in women with breast cancer has been demonstrated.PMID:38616815 | PMC:PMC11010796 | DOI:10.1016/j.conctc.2024.101288 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: E Villegas-Becerril C Jimenez-Garcia L A Perula-de Torres M Espinosa-Calvo C M Bueno-Serrano F Romero-Ruperto F Gines-Santiago M C Moreno-Manzanaro J J Mu ñoz-Gavilan G Montes-Redondo M A Quesada-Roman M C Linares-Ramirez J M Parras-Rejano N Mu ñoz-Alca Source Type: research
Successful treatment of dyshidrotic palmoplantar eczema with tralokinumab
Australas J Dermatol. 2024 Apr 14. doi: 10.1111/ajd.14268. Online ahead of print.ABSTRACTDyshidrotic palmoplantar eczema or pompholyx is considered to be a part of the spectrum of atopic dermatitis with a significant impact on the quality of life and limited treatment options. Tralokinumab is a new fully human monoclonal antibody which neutralizes interleukin 13, a chief cytokine in itch pathogenesis and skin barrier defects. Tralokinumab is FDA-approved for the treatment of atopic dermatitis in adults and EMA-approved for the treatment of atopic dermatitis in adults and adolescents. We, hereby, report a 40-year-old female...
Source: The Australasian Journal of Dermatology - April 15, 2024 Category: Dermatology Authors: Nisha V Parmar Anwar Al Hammadi Source Type: research
Dermatitis and prolonged dysesthesia from the poisonous wood nettle, Dendrocnide meyeniana (Urticaceae)
Australas J Dermatol. 2024 Apr 14. doi: 10.1111/ajd.14252. Online ahead of print.NO ABSTRACTPMID:38616498 | DOI:10.1111/ajd.14252 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 15, 2024 Category: Dermatology Authors: Johannes F Dayrit Bryan Edgar K Guevara Lunardi Bintanjoyo Scott A Norton Source Type: research
Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study
CONCLUSION: TCZ can treat active moderate-to-severe TED, showing high drug compliance and reasonable response to inflammation and extraocular motility abnormality.PMID:38622479 | DOI:10.1007/s10792-024-03117-6 (Source: Herpes)
Source: Herpes - April 15, 2024 Category: Infectious Diseases Authors: Chaeyeon Lee Ji Woong Park Yoon-Duck Kim Kyung In Woo Source Type: research
Sub-acute oral exposure to lowest observed adverse effect level of nivalenol exacerbates atopic dermatitis in mice via direct activation of mitogen-activated protein kinase signal in antigen-presenting cells
This study investigated the immunotoxic effects of the mycotoxin nivalenol (NIV) using antigen-presenting cells and a mouse model of atopic dermatitis (AD). In vitro experiments were conducted using a mouse macrophage cell line (RAW 264.7) and mouse dendritic cell line (DC 2.4). After cells were exposed to NIV (0.19-5 µmol) for 24 h, the production of pro-inflammatory cytokines (IL-1β, IL-6, and TNFα) was quantified. To further investigate the inflammatory cytokine production pathway, the possible involvement of mitogen-activated protein kinase (MAPK) pathways, such as ERK1/2, p-38, and JNK, in NIV exposure was analyzed...
Source: Archives of Toxicology - April 14, 2024 Category: Toxicology Authors: Reo Matsuzaka Hiroki Yamaguchi Chiharu Ohira Tomoe Kurita Naoki Iwashita Yoshiichi Takagi Tomomi Nishino Kyoko Noda Kazutoshi Sugita Masayo Kushiro Shiro Miyake Tomoki Fukuyama Source Type: research
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
ConclusionThe results of this analysis demonstrate that, in combination with TCS, tralokinumab and dupilumab have similar efficacy in the treatment of moderate-to-severe AD at 32 weeks of therapy. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 13, 2024 Category: Dermatology Source Type: research